Table 5.
Adverse events reported during follow-up
| Adverse effect | Overall | CYP2D6 | Test, p-value | G6PD | Test, p-value | ||
|---|---|---|---|---|---|---|---|
| Reduced | Normal | Deficient | Normal | ||||
| Mild urine colour change, n (%) | 79 (63.7) | 17 (51.5) | 62 (50.0) | 1.861, 0.394 | 12 (60.0) | 58 (50.0) | 1.408, 0.843 |
| Haemoglobinuria, n (%) | 14 (11.3) | 1 (3.0) | 13 (10.5) | 1.861, 0.394 | 1 (5.0) | 11 (9.5) | 1.408, 0.843 |
| Abdominal pain, n (%) | 9 (7.3) | 0 (0) | 9 (7.3) | 2.541, 0.206 | 2 (10.0) | 4 (3.4) | 4.637, 0.098 |
| Diarrhoea, n (%) | 9 (7.3) | 1 (3.0) | 8 (6.5) | 0.565, 0.686 | 1 (5.0) | 7 (6.0) | 0.076, 0.963 |
| Vomiting, n (%) | 5 (4.0) | 1 (3.0) | 4 (3.2) | 0.003, 1.0 | 2 (10.0) | 3 (2.6) | 3.838, 0.147 |
| Nausea, n (%) | 4 (3.2) | 1 (3.0) | 3 (2.4) | 0.039, 1.0 | 2 (10.0) | 2 (1.7) | 5.339, 0.069 |
| Dizziness, n (%) | 2 (1.6) | 0 (0) | 2 (1.6) | 0.539, 1.0 | 0 (0) | 2 (1.7) | 0.716, 0.699 |
| Coughing, n (%) | 1 (0.8) | 0 (0) | 1 (0.8) | 0.268, 1.0 | 0 (0) | 1 (0.9) | 0.356, 0.837 |
| Rashes, n (%) | 1 (0.8) | 0 (0) | 1 (0.8) | 0.268, 1.0 | 0 (0) | 1 (0.9) | 0.356, 0.837 |